Home > Annual Financials > VENUS REMEDIES

VENUS REMEDIES Financial Statement Analysis
[BOM: 526953|NSE : VENUSREM]

The Revenues of VENUS REMEDIES have increased by 8.55% YoY .
The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 126.84 % YoY.
COMMUNITY POLL
for VENUS REMEDIES
Please provide your vote to see the results

VENUS REMEDIES Last 5 Annual Financial Results
[BOM: 526953|NSE : VENUSREM]

ConsolidatedMar2026
Mar2025
Mar2024
Mar2023
Mar2022
Revenues ₹653 Cr₹601 Cr₹556 Cr₹600 Cr₹548 Cr
Expenses ₹584 Cr₹542 Cr₹495 Cr₹538 Cr₹494 Cr
Operating Profit (Excl OI) ₹69 Cr₹60 Cr₹60 Cr₹62 Cr₹54 Cr
Other Income ₹16 Cr₹12 Cr₹10 Cr₹8.31 Cr₹20 Cr
Interest ₹0.07 Cr₹0.09 Cr₹0.12 Cr₹0.48 Cr₹13 Cr
Depreciation ₹23 Cr₹26 Cr₹32 Cr₹34 Cr₹35 Cr
Profit Before Tax ₹72 Cr₹45 Cr₹38 Cr₹36 Cr₹49 Cr
Profit After Tax ₹45 Cr₹28 Cr₹27 Cr₹41 Cr₹62 Cr
Consolidated Net Profit ₹45 Cr₹28 Cr₹27 Cr₹41 Cr₹62 Cr
Earnings Per Share (Rs)₹76.90₹33.90₹21.31₹19.87₹30.47
PAT Margin (%)13.366.944.744.786.79
ROE(%)16.798.646.015.909.85
ROCE(%)21.8813.178.677.727.89
Total Debt/Equity(x)0.000.000.080.090.10

Key Financials

Market Cap : ₹ 1,714.2 Cr
Revenue (TTM) : ₹ 837.3 Cr
Net Profit(TTM) : ₹ 121.7 Cr
EPS (TTM) : ₹ 90.8
P/E (TTM) : 14.1

Industry Peers & Returns1W1M1Y
VENUS REMEDIES -8.4% -21.6% 194.9%
SUN PHARMACEUTICAL INDUSTRIES 1.1% -4.2% 4.1%
DIVIS LABORATORIES 7.5% 1.3% 45.7%
TORRENT PHARMACEUTICALS 1.8% -6.3% 26.1%
CIPLA 1.5% -2.3% -17.3%
DR REDDYS LABORATORIES 9.3% 9.5% 4.3%
MANKIND PHARMA 11% 0.9% 1.4%
LUPIN 3.8% -3.1% 1.6%
ZYDUS LIFESCIENCES 5.2% -2.2% 16.3%


VENUS REMEDIES Revenues
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

8.55 %

5 Yr CAGR

4.47 %

Years Revenues % Change
Mar2026 ₹653 Cr
8.55
Mar2025 ₹601 Cr
8.27
Mar2024 ₹556 Cr
-7.44
Mar2023 ₹600 Cr
9.50
Mar2022 ₹548 Cr -


VENUS REMEDIES Operating Profit
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

14.99 %

5 Yr CAGR

6.25 %

Years Operating Profit % Change
Mar2026 ₹69 Cr
14.99
Mar2025 ₹60 Cr
-0.71
Mar2024 ₹60 Cr
-3.36
Mar2023 ₹62 Cr
15.50
Mar2022 ₹54 Cr -

Operating Margins
Y-o-Y

5.95 %

5 Yr CAGR

1.71 %

Years Operating Margin% % Change
Mar2026 10.5%
5.95
Mar2025 9.91%
-8.33
Mar2024 10.81%
4.44
Mar2023 10.35%
5.50
Mar2022 9.81% -

VENUS REMEDIES Profit After Tax
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

59.05 %

5 Yr CAGR

-7.45 %

Years Profit After Tax % Change
Mar2026 ₹45 Cr
59.05
Mar2025 ₹28 Cr
7.25
Mar2024 ₹27 Cr
-34.77
Mar2023 ₹41 Cr
-34.07
Mar2022 ₹62 Cr -

PAT Margins
Y-o-Y

92.51 %

5 Yr CAGR

18.44 %

Years PAT Margin(%) % Change
Mar2026 13.36 %
92.51
Mar2025 6.94 %
46.41
Mar2024 4.74 %
-0.84
Mar2023 4.78 %
-29.60
Mar2022 6.79 % -

VENUS REMEDIES Earnings Per Share (EPS)
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

126.84 %

5 Yr CAGR

26.04 %

Years EPS % Change
Mar2026 ₹77
126.84
Mar2025 ₹34
59.08
Mar2024 ₹21
7.25
Mar2023 ₹20
-34.79
Mar2022 ₹30 -

VENUS REMEDIES Return on Capital Employed (ROCE)
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

66.14 %

5 Yr CAGR

29.05 %

Years ROCE % Change
Mar2026 21.88%
66.14
Mar2025 13.17%
51.90
Mar2024 8.67%
12.31
Mar2023 7.72%
-2.15
Mar2022 7.89% -

VENUS REMEDIES Share Price vs Sensex

Current Share Price : ₹1,279.3
Current MarketCap: ₹ 1,714.2 Cr
Updated EOD on :Oct 29,2026

Share Price Returns(%) 1 Week 1 Month 1 Year
VENUS REMEDIES

-8.4%

-21.6%

194.9%

SENSEX

1.2%

0.4%

-12.2%

VENUS REMEDIES related INDICES

BSE Indices1W1M1Y
BSE HEALTHCARE 4.9% -3.7% 9.4%
No NSE index found

You may also like the below Video Courses


FAQ about VENUS REMEDIES Financials


How the annual revenues of VENUS REMEDIES have changed ?

The Revenues of VENUS REMEDIES have increased by 8.55% YoY .

How the Earnings per Share (EPS) of VENUS REMEDIES have changed?

The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 126.84 % YoY .